Non-Exudative Age-Related Macular Degeneration (Dry AMD)

Sponsor - Iveric Bio (Open to Enrollment)

Study: GATHER2 ISEE2008 
A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION

Sponsor - Gemini Therapeutics (Open to Enrollment)

Study: ReGAtta GEM-CL-10302 
A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103

Sponsor – Genentech (Recruitment/Not yet Open)

Study: GR42558
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION (GAllegOLE)

Sponsor - Genentech (Open to Enrollment) Study: GALLEGO
A PHASE II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION (GALLEGO)
https://clinicaltrials.gov/ct2/show/NCT03972709?term=gallego&rank=1

Sponsor - Ionis (Open to Enrollment)

Study: GOLDEN
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
https://clinicaltrials.gov/ct2/show/NCT03815825?term=isis+696844&rank=1

Sponsor - Stealth BioTherapeutics (Open to Enrollment)

Study: SPIAM-202
APhase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy
https://clinicaltrials.gov/ct2/show/NCT03891875?term=spiam&rank=1

Sponsor - Apellis (Closed to Enrollment)

Study: OAKS 
A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Sponsor - Allergan (Recruitment/Not Yet Open)

Study: IMAGINE
Efficacy and Safety of Brimonidine Drug Delivery System (Brimo DDS®) in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration: A Phase III Randomized, Double-masked, Sham Procedure-controlled Trial


Previous Dry AMD Studies:

Principal Investigator, 2016 - 2017
Sponsor: Genentech/Roche
Study: OMASPECT
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY
https://clinicaltrials.gov/ct2/show/NCT02745119?term=OMASPECT&rank=1

Principal Investigator, 2014 - 2017
Sponsor: Genentech/Roche
Study: CHROMA – Geographic Atrophy (GA)

A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/results?term=CHROMA&Search=Search